ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag anti inflammatory drugs ecology

The Ecology of Tumors
Paraic A. Kenny, Celeste M. Nelson, and Mina J. Bissell | Apr 1, 2006 | 10+ min read
FEATUREThe Ecology of Tumors   Courtesy of Nasa Ames Research CenterBy perturbing the microenvironment, wounds and infection may be key to tumor development.BY PARAIC A. KENNY, CELESTE M. NELSON, AND MINA J. BISSELLNo tumor is an island. Chemical and physical forces exerted by the diverse cellular populations that surround a tumor - its so-called microenvironment - shape development and progression. Manipulating these 'ecologi
A green and white fish swimming underwater
Rockfish Genes Hold Clues to Human Longevity
Natalia Mesa, PhD | Jan 12, 2023 | 3 min read
By analyzing the genomes of 23 remarkably long-lived fish species, a study found two metabolic pathways associated with longevity.
Drugging the Environment
Megan Scudellari | Aug 1, 2015 | 10+ min read
Humans have spiked ecosystems with a flood of active pharmaceuticals. The drugs are feminizing male fish, confusing birds, and worrying scientists.
A fruit bat in the hands of a researcher
How an Early Warning Radar Could Prevent Future Pandemics
Amos Zeeberg, Undark | Feb 27, 2023 | 8 min read
Metagenomic sequencing can help detect unknown pathogens, but its widespread use faces challenges.
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Image of the tissue surrounding a pancreatic tumor thickening and scarring.
How Pancreas Injuries Can Cause Cancer in Mice
Dan Robitzski | Nov 9, 2021 | 4 min read
A key mutation turns healing cells into cancer promoters.
Updated Sept 1
coronavirus pandemic news articles covid-19 sars-cov-2 virology research science
Follow the Coronavirus Outbreak
The Scientist | Feb 20, 2020 | 10+ min read
Saliva tests screen staff and students at University of Illinois; Study ranks species most susceptible to SARS-CoV-2 infection; COVID-19 clinical trials test drugs that inhibit kinin system
Chloroquine Protects Against Zika In Vitro
Marcia Triunfol | May 12, 2016 | 3 min read
The antimalarial drug reduces the number of infected Vero and human brain microvascular endothelial cells—among other cell types—in culture, researchers report in a preprint.
Stem Cells: Safe Haven For TB
Nsikan Akpan | Feb 5, 2013 | 3 min read
Tuberculosis bacteria find shelter from drugs and the body’s defenses in bone marrow stem cells.

Run a Search

ADVERTISEMENT